Prevents organ rejection. ANDA 203575, held by Ph Health. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 203575 (Mycophenolate Mofetil Hydrochloride), held by Ph Health, was first approved by FDA on Oct 28, 2016, with 7 approved supplements and 0 published complete response letters.
Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 12REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 9REMS | Approved | None posted |
| May 13, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 15, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 11, 2021 | Supplement 7REMS | Approved | None posted |
| Apr 21, 2021 | Supplement 6REMS | Approved | None posted |
| Jan 15, 2021 | Supplement 4REMS | Approved | None posted |
| Oct 28, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters